General
Preferred name
Etacrynic acid
Synonyms
ETHACRYNIC ACID ()
Edecrin ()
Hydromedin ()
ETHACRYNATE SODIUM ()
ethacrynic acid sodium ()
NSC-85791 ()
MK-595 ()
Acide etacrynique ()
NSC-624008 ()
Reomax ()
Acido etacrinico ()
Ethacrynate ()
Ethacrynic acid sodium salt ()
Sodium etacrynate ()
Etacrynate sodium ()
Sodium ethacrynate ()
Ethacrynic Acid-d5 ()
P&D ID
PD002338
CAS
58-54-8
6500-81-8
1330052-59-9
Tags
available
covalent binder
drug
Approved by
FDA
First approval
1967
Drug indication
Cardiovascular disease
High blood pressure
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Ethacrynic acid is a loop diuretic.
(GtoPdb)
DESCRIPTION
Ethacrynic acid has anti-inflammatory and anticancer activity. Ethacrynic acid is an orally active diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferase (GSTs) and Wnt signaling pathways. Ethacrynic acid is a radiosensitizer. Ethacrynic acid can inhibit airway smooth muscle (ASM) contraction in mice. Ethacrynic acid can increase the outflow of aqueous humor from the eye for the study of glaucoma[1][2][3][4][5][6][7][8][9].
PRICE
29
DESCRIPTION
Ethacrynic acid is a loop diuretic with anticancer activity. It is used for the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.
(Enamine Bioactive Compounds)
DESCRIPTION
Ethacrynic acid (Edecrin) is a nonsulfonamide loop diuretic that inhibits the activity of the Na+/K+/2Cl- cotransporter NKCC2 in the thick ascending limb of the loop of Henle. It also inhibits glutathione S-transferase and Wnt signalling, producing cytotoxicity in chronic lymphocytic leukaemia cells and other tumour cells.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
8
Organisms
3
Compound Sets
25
ChEMBL Approved Drugs
ChEMBL Drugs
CovalentInDB
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
65
Molecular Weight
302.01
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
3.61
TPSA
63.6
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Membrane Transporter/Ion Channel
Metabolism
NF-κB
oxidation-reduction
Immunology/Inflammation
Metabolic Enzyme/Protease
Neuronal Signaling
Stem Cell/Wnt
NF-¦ÊB
MOA
NKCC inhibitor
GST inhibitor
sodium/potassium/chloride transporter inhibitor
Indication
hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome
Disease Area
cardiology, gastroenterology, nephrology, rheumatology
Target
ATP1A1, SLC12A1
Calcium Channel
Glutathione S-transferase
NO Synthase
Wnt
Proton Pump
GST
NKCC2
Therapeutic Class
Cardiovascular Agents
Diuretics
Source data
